The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition

(2011) H. Shi et al.   CANCER RESEARCH

KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites

(2011) K. Omholt et al.   CLINICAL CANCER RESEARCH

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification

(2011) Jun Guo et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance

(2011) Lu Si et al.   JOURNAL OF CLINICAL ONCOLOGY

The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma

(2011) Ruixia Liang et al.   Pigment Cell & Melanoma Research

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor

(2010) Mrinal M. Gounder et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells

(2010) Y. N. V. Gopal et al.   CANCER RESEARCH

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

(2010) Despina Handolias et al.   Pigment Cell & Melanoma Research

KIT as a Therapeutic Target in Melanoma

(2009) Maria C. Garrido et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

c-Kit mutants require hypoxia-inducible factor 1α to transform melanocytes

(2009) G Monsel et al.   ONCOGENE

MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth

(2008) Yuichi Takayama et al.   CANCER LETTERS

Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression

(2008) K. S.M. Smalley et al.   CANCER RESEARCH

KIT Gene Mutations and Copy Number in Melanoma Subtypes

(2008) C. Beadling et al.   CLINICAL CANCER RESEARCH

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

(2008) X. Jiang et al.   CLINICAL CANCER RESEARCH

Major Response to Imatinib Mesylate in KIT-Mutated Melanoma

(2008) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

(2008) Jose Lutzky et al.   Pigment Cell & Melanoma Research

Stem cell factor induces ERM proteins phosphorylation through PI3K activation to mediate melanocyte proliferation and migration

(2008) Songhee Jeon et al.   Pigment Cell & Melanoma Research

KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential

(2008) Katerina Kontogianni-Katsarou et al.   WORLD JOURNAL OF GASTROENTEROLOGY